Lung Cancer Clinical Trial
Official title:
Impact of a Patient's Lung Cancer Diagnosis on Relatives' Understanding of Genetic Risk Information and Receptivity to Quit Smoking
| Verified date | July 16, 2010 |
| Source | National Institutes of Health Clinical Center (CC) |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
This study will explore beliefs and knowledge about genetics and smoking among smokers who
have a first or second degree relative with advanced lung cancer, and whether their
understanding of genetic risk influences their desire to quit smoking.
Healthy adult smokers between 18 and 55 years of age who are first or second degree relatives
(e.g., siblings, children, grandchildren, nieces, nephews, grandnieces or grandnephews) of a
patient with advanced lung cancer who is receiving care at the Moffitt Cancer Center and
Research Institute in Tampa, Fla. and the GUMC/LCCC, may be eligible for this study.
Participants must be able to complete computer online surveys.
Participants log on to a password-protected website to complete online educational sessions
and surveys. The educational sessions include information on: 1) the role of smoking and
genetics in the development of lung cancer; 2) glutathione S transferase (GSTM1), an enzyme
made by the GSTM1 gene that "cleans up" toxins such as cigarette smoke and that may play a
role in preventing lung cancer from developing; 3) pros and cons of being tested for GSTM1;
and 5) a series of questions and answers about genetic testing. Participants are offered free
genetic testing for GSTM1, and those who wish to be tested are sent materials to collect a
sample from inside the cheek using a mouth rinse and return it to a laboratory at Duke
University Medical Center. They later receive their results online.
Participants also complete online surveys that ask about their risk perceptions, beliefs and
attitudes related to lung cancer, emotional responses to their relative's diagnosis, smoking
history and motivation to quit, reactions to information about smoking and genetic risk, and
interest in receiving smoking cessation services. They are asked to review depictions and
descriptions of smoking cessation materials offered through a quit smoking program at Duke
University Medical Center and to evaluate the extent to which the various materials might be
helpful. They are offered additional information among categories they can choose from.
Participants are surveyed again by telephone 6 months after completing the online surveys.
| Status | Completed |
| Enrollment | 757 |
| Est. completion date | July 16, 2010 |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 55 Years |
| Eligibility |
- INCLUSION CRITERIA: The target sample for the study is healthy adult smokers ages 18 to 55 who are first or second degree blood relatives (e.g., siblings, sons, daughters, grandsons, granddaughters, nieces, nephews, grandnieces, grandnephews) of a late stage lung cancer patient (Stage IIIB or IV) who is receiving care at MCC. Aside from age and blood relationship to the lung cancer patient, eligibility criteria also will include the following: No current or previous diagnosis of cancer; Has access and some willingness to use the internet; Is willing to be contacted by NIH study staff; Has a score lower than 14 on the Centers for Epidemiological Survey of Depression (CESD); Is English speaking. |
| Country | Name | City | State |
|---|---|---|---|
| United States | National Human Genome Research Institute (NHGRI), 9000 Rockville Pike | Bethesda | Maryland |
| Lead Sponsor | Collaborator |
|---|---|
| National Human Genome Research Institute (NHGRI) |
United States,
Alexandrie AK, Nyberg F, Warholm M, Rannug A. Influence of CYP1A1, GSTM1, GSTT1, and NQO1 genotypes and cumulative smoking dose on lung cancer risk in a Swedish population. Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):908-14. — View Citation
Aspinwall LG, Taylor SE. Effects of social comparison direction, threat, and self-esteem on affect, self-evaluation, and expected success. J Pers Soc Psychol. 1993 May;64(5):708-22. — View Citation
Belogubova EV, Togo AV, Karpova MB, Kuligina ESh, Buslova KG, Ulibina JM, Lemehov VG, Romanenko SM, Shutkin VA, Hanson KP, Hirvonen A, Imyanitov EN. A novel approach for assessment of cancer predisposing roles of GSTM1 and GSTT1 genes: use of putatively cancer resistant elderly tumor-free smokers as the referents. Lung Cancer. 2004 Mar;43(3):259-66. — View Citation
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|